Health Care Cost Analysis of PPI or P-CAB-First Treatment in Patients With Gastroesophageal Reflux Disease.

Authors:
Miwa H; Shiotani A; Takeda M; Eda M; Kato T and 1 more

Journal:
J Clin Gastroenterol

Publication Year: 2023

DOI:
10.1097/MCG.0000000000001685

PMCID:
PMC9983749

PMID:
35316226

Journal Information

Full Title: J Clin Gastroenterol

Abbreviation: J Clin Gastroenterol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"H.M. is currently receiving grants from Daiichi-Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd., and lecture/other fees from AstraZeneca K.K., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd. A.S. is currently receiving grants from Daiichi Sankyo Co., Ltd. and Takeda Pharmaceutical Co., Ltd., research grants from AstraZeneca K.K., and lecture/other fees from Daiichi Sankyo Co., Ltd. and Takeda Pharmaceutical Co., Ltd. M.T., M.E., and T.Y. is full-time employees of AstraZeneca K.K., Osaka, Japan. T.K. is a full-time employee of EP-CRSU Co., Ltd, Tokyo, Japan of which AstraZeneca is a client."

Evidence found in paper:

"This study and its corresponding analyses were supported and funded by AstraZeneca K.K., Osaka, Japan. The publication fee for this paper was provided by AstraZeneca K.K., Osaka, Japan."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025